AIM ImmunoTech Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
AIM NYSE American 2830 aimimmuno.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for AIM ImmunoTech Inc.

AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer - Jun 8th, 2026 6:33 am
AIM ImmunoTech Releases Virtual Investor ‘What This Means’ Video Segment Discussing Ampligen’s Potential in Ebola Virus Disease Preparedness - Jun 4th, 2026 6:55 am
AIM Stock Soars Over 200% As Pancreatic Cancer Trial Hits Enrollment Milestone Early — CEO Sees 'Value-Inflection Period' Ahead - Jun 1st, 2026 8:19 am
AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones - Jun 1st, 2026 6:58 am
AIM ImmunoTech Announces Emerging Ebola Opportunity for Ampligen Amid Escalating Global Health Concerns and WHO Emergency Declaration - May 27th, 2026 6:47 am
AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement - May 20th, 2026 1:02 pm
AIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical Priorities - May 19th, 2026 6:02 am
AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer - May 14th, 2026 6:41 am
Transcript: Aimia Q1 2026 Earnings Conference Call - May 13th, 2026 7:47 am
AIM ImmunoTech, Inc. Announces Exercise of Warrants for Approx. $4.2 Million in Gross Proceeds - May 8th, 2026 6:40 am
AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential - May 7th, 2026 6:23 am
AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP - Apr 16th, 2026 7:00 am
AIM ImmunoTech Provides Routine Update on Annual Filings - Apr 13th, 2026 4:00 pm
AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event - Apr 9th, 2026 6:00 am
AIMIA PROVIDES UPDATE ON ITS SHARE BUYBACKS - Apr 1st, 2026 7:04 am
We Might See A Profit From Aimia Inc. (TSE:AIM) Soon - Mar 26th, 2026 6:51 am
Aimia Q4 Earnings Call Highlights - Mar 24th, 2026 9:36 am
Thermo Fisher Scientific (TMO) Partners With AIM ImmunoTech on Phase 3 Cancer Trial - Mar 24th, 2026 8:43 am
AIMIA REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - Mar 24th, 2026 4:00 am
AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors - Mar 18th, 2026 6:36 am